Skip to Main Content
Recruiting

TRAIT: Radioactive Iodine in Differentiated Thyroid Cancer

About this study

Differentiated thyroid cancer (DTC) is a type of thyroid cancer. Scientists have developed new drugs to target the genetic mutations (changes in a person’s DNA) that drive this cancer. These type of drugs are called targeted therapy and can shrink tumors in many cases. Research in adults has shown that these drugs can increase the tumor’s absorption of radioactive iodine. Radioactive iodine is a common treatment for thyroid cancer.

Patients in the TRAIT clinical trial have DTC that has spread to the lungs. These patients will receive targeted therapy for their cancer. They will also follow a low-iodine diet for 7–14 days and will have 2 whole-body scans to check how much radioactive iodine their cancer absorbs. The first scan will happen before they start targeted therapy, and the second will take place about 4 weeks later. 

Researchers will compare the scans to see if there is a difference. Doctors will continue to check each patient’s medical records for up to 5 years to gather more information.

This study will help us learn if targeted therapy affects the way radioactive iodine is taken up by the cancer. What we learn could help us make better treatment plans in the future.

Eligibility overview

  • Differentiated thyroid cancer
  • Infants to adults
  • Presence of an NTRK fusion, RET fusion, ALK fusion, BRAF V600 mutation, or other targetable alteration
  • Metastatic disease in the lungs

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

Thyroid Therapy to Increase RAI Uptake in Patients with Metastatic Differentiated Thyroid Cancer (TRAIT)

Study goal:

To study radioactive iodine and targeted therapy for differentiated thyroid cancer

Age:

Infants to adults

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more